Detalhe da pesquisa
1.
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(10): 1094-1108, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37714168
2.
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
J Clin Oncol
; 42(3): 283-299, 2024 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37864337